BDX Stock Forecast & Price Target

Becton Dickinson has demonstrated robust growth across its divisions, with the Medical Surgical (MMS) segment reporting sales of $888 million in FQ3'25, a 5.3% year-over-year increase, driven primarily by strong performance in Infusion Systems and growth in Pharmacy Automation. The company’s MedTech business has consistently grown by over 6% annually since the launch of BD 2025, with margins accelerating, indicating a successful strategic direction. Additionally, the Biologics sector has shown double-digit growth, contributing to a positive outlook for the company's overall financial performance, as evidenced by the MDS segment's FY24 sales of $4.43 billion, representing a 3.2% year-over-year increase.

Becton Dickinson has reaffirmed its organic revenue growth outlook at 3.0-3.5% year-over-year, a downward adjustment from the prior forecast of 4.0-4.5%. In the third fiscal quarter of 2025, the company reported sales of $1.25 billion, reflecting a year-over-year decline of 1.1% (excluding foreign exchange), attributed to low-single digit declines in key segments such as Biosciences and Diagnostic Solutions. Additionally, external challenges, including volume-based procurement headwinds in China and a slowdown in demand within the Bioscience Pharma sector due to reduced government research grants and slower-than-expected recovery, have contributed to a negative outlook for the company's growth trajectory.